Aurobindo Pharma shares hit a day high of Rs 1,700.70 on 1 October, up 2%, after its arm Acrotech Biopharma launched Adquey in the US.

Aurobindo Pharma disclosed the launch to the exchanges late on Wednesday. That left investors with the news before the market opened on Thursday.

Adquey is an ointment for atopic dermatitis, a common form of eczema that leaves skin dry and itchy.

It treats mild to moderate cases in adults and in children aged two and above. It does not contain steroids.

Otsuka Pharmaceutical discovered the drug. Acrotech Biopharma then licensed it for sale in the United States.

To back the launch, Aurobindo has set up a separate dermatology business unit. It will handle sales and help grow this part of the business.

Adquey will compete in a US market worth around $1.3 billion for the 12 months ending July 2026, based on IQVIA data.

Acrotech is a step-down subsidiary of Aurobindo, which means the parent holds it through another group company. The firm was formed as a global platform to sell new proprietary medicines.

Acrotech President Ashish Anvekar called the launch ‘an important milestone’ for the firm. He said it marks Acrotech’s entry into US dermatology.

NSE also lists a share buyback for the company, with an ex-date of 17 April.

At 10:46 am, Aurobindo Pharma shares traded at Rs 1,683.10 on NSE, up by 0.66%. The stock sits below its 52-week high of Rs 1,740, set on 24 September.

It has gained 54.95% over the past year and 41.06% so far in 2026. About 2.94 lakh shares had changed hands by 10:46 am, and the company’s market value stands at about Rs 96,842 crore.

Unlock profitable opportunities every day! Tradz by EquityPandit provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Tradz by EquityPandit and start winning now!